Finch Therapeutics Group, Inc. (FNCH)
USD 12.74
(-0.08%)
USD 12.74
(-0.08%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 48.11 Million USD | -28.44% |
| 2022 | 67.22 Million USD | 190.46% |
| 2021 | 23.14 Million USD | -91.13% |
| 2020 | 261.05 Million USD | 60.05% |
| 2019 | 163.1 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 31.05 Million USD | -35.45% |
| 2024 Q2 | 31.35 Million USD | 0.98% |
| 2023 Q1 | 46.08 Million USD | -31.45% |
| 2023 FY | 48.11 Million USD | -28.44% |
| 2023 Q4 | 48.11 Million USD | 42.85% |
| 2023 Q3 | 33.68 Million USD | -13.56% |
| 2023 Q2 | 38.96 Million USD | -15.46% |
| 2022 Q2 | 69.2 Million USD | 178.6% |
| 2022 FY | 67.22 Million USD | 190.46% |
| 2022 Q1 | 24.84 Million USD | 7.33% |
| 2022 Q4 | 67.22 Million USD | 0.19% |
| 2022 Q3 | 67.1 Million USD | -3.04% |
| 2021 Q1 | 26.49 Million USD | -89.85% |
| 2021 FY | 23.14 Million USD | -91.13% |
| 2021 Q4 | 23.14 Million USD | 75.63% |
| 2021 Q3 | 13.17 Million USD | -40.47% |
| 2021 Q2 | 22.13 Million USD | -16.45% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q4 | 261.05 Million USD | 0.0% |
| 2020 FY | 261.05 Million USD | 60.05% |
| 2019 FY | 163.1 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | -897.126% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -1924.874% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -23.593% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 63.727% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -1631.234% |
| Better Therapeutics, Inc. | 23.84 Million USD | -101.791% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -480.77% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -382.354% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -82.661% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -51.373% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 30.709% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | -505.506% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 69.42% |
| Innovation1 Biotech Inc. | 3.5 Million USD | -1272.265% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -125.981% |
| Molecular Templates, Inc. | 31.17 Million USD | -54.345% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | -284.429% |
| NexImmune, Inc. | 5.08 Million USD | -846.279% |
| Orgenesis Inc. | 35.53 Million USD | -35.39% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -191.37% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -17958.736% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -1996.037% |
| Scopus BioPharma Inc. | 7.45 Million USD | -545.401% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 90.271% |
| Statera Biopharma, Inc. | 22.67 Million USD | -112.163% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -340.819% |
| Trevena, Inc. | 48.26 Million USD | 0.313% |
| Vaxxinity, Inc. | 30.94 Million USD | -55.478% |
| Vaccinex, Inc. | 5.94 Million USD | -709.677% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -2344.246% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -25.377% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -1642.169% |